NI201100189A - Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos - Google Patents
Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismosInfo
- Publication number
- NI201100189A NI201100189A NI201100189A NI201100189A NI201100189A NI 201100189 A NI201100189 A NI 201100189A NI 201100189 A NI201100189 A NI 201100189A NI 201100189 A NI201100189 A NI 201100189A NI 201100189 A NI201100189 A NI 201100189A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compounds
- kinases
- methods
- raf
- indications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen compuestos y sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos, formas de los mismos y usos de los mismos En algunos aspectos y formas de realización, los compuestos descriptos o sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos y formas de los mismos son activos en cada una de las proteína quinasas BRaf y c-Raf-1, y también pueden ser activos en cualquiera, o ambas, de las proteínas quinasas A-Raf y B-Raf V600E. También se describen métodos de uso de los mismos para tratar enfermedades y condiciones, incluyendo melanoma, cáncer colorrectal, cáncer de tiroides, cáncer ovárico y cáncer del tracto biliar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17605409P | 2009-05-06 | 2009-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201100189A true NI201100189A (es) | 2012-01-11 |
Family
ID=42236712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201100189A NI201100189A (es) | 2009-05-06 | 2011-11-03 | Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120122860A1 (es) |
| EP (2) | EP2427462A1 (es) |
| JP (2) | JP2012526128A (es) |
| KR (1) | KR20140014386A (es) |
| CN (1) | CN102459262A (es) |
| AR (1) | AR076749A1 (es) |
| AU (1) | AU2010246005A1 (es) |
| BR (1) | BRPI1013843A2 (es) |
| CA (1) | CA2759997A1 (es) |
| CL (1) | CL2011002739A1 (es) |
| CR (1) | CR20110562A (es) |
| EC (1) | ECSP11011437A (es) |
| IL (1) | IL215908A0 (es) |
| MA (1) | MA34042B1 (es) |
| MX (1) | MX2011011737A (es) |
| NI (1) | NI201100189A (es) |
| NO (1) | NO20111508A1 (es) |
| PE (1) | PE20120518A1 (es) |
| RU (1) | RU2011149485A (es) |
| SG (1) | SG175810A1 (es) |
| TW (1) | TW201041888A (es) |
| WO (2) | WO2010129567A1 (es) |
| ZA (1) | ZA201108124B (es) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007002433A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| UA105813C2 (uk) | 2009-11-06 | 2014-06-25 | Плексікон, Інк. | Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти) |
| MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| BR112012015745A2 (pt) * | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compostos e métodos para a modulação de quinase, e indicações dos mesmos |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| JP6112512B2 (ja) * | 2010-12-01 | 2017-04-12 | レクシ ファーマ インコーポレイテッド | 難治性癌を治療するための方法 |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012106559A1 (en) * | 2011-02-02 | 2012-08-09 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
| AU2012214762B2 (en) * | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI558702B (zh) * | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
| WO2012138809A1 (en) * | 2011-04-05 | 2012-10-11 | Dawei Zhang | Heterocyclic compounds as kinase inhibitors |
| BR112013029163A2 (pt) | 2011-05-17 | 2017-01-31 | Plexxikon Inc | modulação quinase e indicações dos mesmos |
| CA2846574C (en) * | 2011-08-26 | 2020-07-07 | Neupharma, Inc. | Quinoxaline sulfonamide derivates for use as kinase inhibitors |
| CN102993199A (zh) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
| CA2848506C (en) | 2011-09-14 | 2020-07-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2013043935A1 (en) | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| WO2013049701A1 (en) | 2011-09-30 | 2013-04-04 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| JP6013029B2 (ja) * | 2012-05-25 | 2016-10-25 | 千葉県 | 抗癌剤 |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US9150570B2 (en) * | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| US9221815B2 (en) * | 2012-07-03 | 2015-12-29 | Ratiopharm Gmbh | Solid state form of vemurafenib choline salt |
| DE102012016908A1 (de) * | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN105712992B (zh) * | 2012-09-29 | 2018-10-26 | 上海科州药物研发有限公司 | 作为cMet抑制剂的化合物及其制备方法和用途 |
| US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| AU2013348116A1 (en) | 2012-11-20 | 2015-06-11 | Principia Biopharma Inc. | Azaindole derivatives as JAK3 inhibitors |
| US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| EP2970270A1 (en) | 2013-03-14 | 2016-01-20 | ratiopharm GmbH | Solid state forms of vemurafenib hydrochloride |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| JP6325078B2 (ja) | 2013-03-15 | 2018-05-16 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環式化合物およびその使用 |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| EP3004060B1 (en) * | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| WO2015075749A1 (en) * | 2013-11-22 | 2015-05-28 | Laurus Labs Private Limited | Novel processes for the preparation of vemurafenib |
| CZ2013943A3 (cs) | 2013-11-27 | 2015-06-03 | Zentiva, K.S. | Krystalické formy vemurafenibu |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
| JP6832846B2 (ja) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環化合物およびその用途 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CZ2015250A3 (cs) | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| CN113754656A (zh) | 2015-09-21 | 2021-12-07 | 普莱希科公司 | 杂环化合物及其应用 |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| BR112018011475A2 (pt) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compostos e métodos para modulação de quinase e indicação para a mesma |
| US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| WO2017218544A1 (en) * | 2016-06-13 | 2017-12-21 | Chemocentryx, Inc. | Methods of treating pancreatic cancer |
| CN107722013B (zh) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | 去氮嘌呤类化合物及其药物组合物、制备方法和用途 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| MX2021014356A (es) | 2016-11-23 | 2022-11-24 | Chemocentryx Inc | Metodo para tratar glomeruloesclerosis segmentaria focal. |
| AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| AU2018209164B2 (en) * | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| TWI805599B (zh) | 2017-07-25 | 2023-06-21 | 美商第一三共公司 | 激酶調節化合物之調配物 |
| WO2019075086A1 (en) | 2017-10-11 | 2019-04-18 | Chemocentryx, Inc. | TREATMENT OF FOCAL SEGMENTAL GLOBEROSCLEROSIS WITH CCR2 ANTAGONISTS |
| EP3694855A1 (en) | 2017-10-13 | 2020-08-19 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| CN112165958A (zh) | 2017-10-27 | 2021-01-01 | 普莱希科公司 | 调制激酶的化合物的制剂 |
| EP3737382A1 (en) * | 2018-01-10 | 2020-11-18 | Cura Therapeutics, LLC | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
| CA3089678A1 (en) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN112119072A (zh) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | 用于ido和tdo调节的化合物和方法，以及其适应症 |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2020016243A1 (en) * | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05002444A (es) | 2002-09-06 | 2005-09-30 | Insert Therapeutics Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
| WO2007002433A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
| DE102005034406A1 (de) | 2005-07-22 | 2007-02-01 | Ratiopharm Gmbh | Neue Salze von Rosiglitazon |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| CN101808994B (zh) * | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
-
2010
- 2010-04-30 TW TW099113997A patent/TW201041888A/zh unknown
- 2010-05-04 CA CA2759997A patent/CA2759997A1/en not_active Abandoned
- 2010-05-04 EP EP10717408A patent/EP2427462A1/en not_active Withdrawn
- 2010-05-04 US US13/318,760 patent/US20120122860A1/en not_active Abandoned
- 2010-05-04 BR BRPI1013843A patent/BRPI1013843A2/pt not_active IP Right Cessation
- 2010-05-04 SG SG2011078979A patent/SG175810A1/en unknown
- 2010-05-04 JP JP2012509907A patent/JP2012526128A/ja active Pending
- 2010-05-04 KR KR1020117029018A patent/KR20140014386A/ko not_active Application Discontinuation
- 2010-05-04 EP EP10717980A patent/EP2427433A1/en not_active Withdrawn
- 2010-05-04 RU RU2011149485/02A patent/RU2011149485A/ru not_active Application Discontinuation
- 2010-05-04 JP JP2012509906A patent/JP2012526127A/ja active Pending
- 2010-05-04 US US12/773,798 patent/US8198273B2/en active Active
- 2010-05-04 CN CN2010800305090A patent/CN102459262A/zh active Pending
- 2010-05-04 MA MA34424A patent/MA34042B1/fr unknown
- 2010-05-04 AU AU2010246005A patent/AU2010246005A1/en not_active Abandoned
- 2010-05-04 MX MX2011011737A patent/MX2011011737A/es not_active Application Discontinuation
- 2010-05-04 WO PCT/US2010/033571 patent/WO2010129567A1/en active Application Filing
- 2010-05-04 WO PCT/US2010/033576 patent/WO2010129570A1/en active Application Filing
- 2010-05-04 PE PE2011001867A patent/PE20120518A1/es not_active Application Discontinuation
- 2010-05-05 AR ARP100101517A patent/AR076749A1/es not_active Application Discontinuation
-
2011
- 2011-10-25 IL IL215908A patent/IL215908A0/en unknown
- 2011-10-26 CR CR20110562A patent/CR20110562A/es unknown
- 2011-11-01 EC EC2011011437A patent/ECSP11011437A/es unknown
- 2011-11-03 CL CL2011002739A patent/CL2011002739A1/es unknown
- 2011-11-03 NO NO20111508A patent/NO20111508A1/no not_active Application Discontinuation
- 2011-11-03 NI NI201100189A patent/NI201100189A/es unknown
- 2011-11-04 ZA ZA2011/08124A patent/ZA201108124B/en unknown
-
2012
- 2012-06-07 US US13/491,480 patent/US20120245174A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140014386A (ko) | 2014-02-06 |
| MA34042B1 (fr) | 2013-03-05 |
| TW201041888A (en) | 2010-12-01 |
| JP2012526127A (ja) | 2012-10-25 |
| CN102459262A (zh) | 2012-05-16 |
| SG175810A1 (en) | 2011-12-29 |
| CL2011002739A1 (es) | 2012-04-09 |
| ECSP11011437A (es) | 2011-12-30 |
| WO2010129567A1 (en) | 2010-11-11 |
| US20100286142A1 (en) | 2010-11-11 |
| IL215908A0 (en) | 2012-01-31 |
| MX2011011737A (es) | 2011-12-08 |
| AR076749A1 (es) | 2011-07-06 |
| EP2427462A1 (en) | 2012-03-14 |
| CR20110562A (es) | 2012-02-09 |
| US8198273B2 (en) | 2012-06-12 |
| JP2012526128A (ja) | 2012-10-25 |
| US20120245174A1 (en) | 2012-09-27 |
| RU2011149485A (ru) | 2013-06-20 |
| PE20120518A1 (es) | 2012-05-24 |
| NO20111508A1 (no) | 2011-12-02 |
| BRPI1013843A2 (pt) | 2016-04-12 |
| EP2427433A1 (en) | 2012-03-14 |
| ZA201108124B (en) | 2014-04-30 |
| WO2010129570A1 (en) | 2010-11-11 |
| US20120122860A1 (en) | 2012-05-17 |
| AU2010246005A1 (en) | 2011-12-01 |
| CA2759997A1 (en) | 2010-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201100189A (es) | Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos | |
| UY31829A (es) | Compuestos y métodos para modulación de cinasas, e indicaciones para ello | |
| CO6551689A2 (es) | Compuestos y métodos para la modulación de cinasas, e indicadores para ello | |
| NI201100168A (es) | Derivados de pirrolo [2,3-b] piridina para la inhibición de quinasas raf | |
| CY1120664T1 (el) | Χρησεις και συνθεσεις για αντιμετωπιση διαπυητικης ιδρωταδενιτιδας (δι) | |
| CL2019000334A1 (es) | Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357) | |
| AR063532A1 (es) | Anticuerpos e inmunoconjugados y sus usos | |
| ECSP088831A (es) | Anticuerpos anti-tat226 e inmunoconjugados | |
| CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
| CR20120536A (es) | Compuestos y métodos para la modulación de quinasa e indicaciones de la misma | |
| AR060978A1 (es) | Anticuerpos e inmunoconjugados y sus usos | |
| AR076105A1 (es) | Derivados pirrol[2,3-b]piridina para inhibir la raf quinasa | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| SV2006002283A (es) | Formulaciones | |
| BRPI1013771A2 (pt) | "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." | |
| SV2007002813A (es) | Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables | |
| CR20120221A (es) | Compuestos y métodos para la modulación de cinasas, e indicaciones para ello | |
| TR201821029T4 (tr) | Geliştirilmiş antı-IL-23p19 antikorları. | |
| ECSP088733A (es) | Anticuerpos anti-5t4 y usos de los mismos | |
| CR10147A (es) | "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos" | |
| BRPI0511396A (pt) | derivados de retinal e métodos para uso no tratamento de enfermidades visuais | |
| BRPI0507680A (pt) | partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas | |
| BRPI0912292A2 (pt) | composições e métodos para o uso de células no tratamento do tecido cardíaco. | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком |